FLASCO / Clinical Trials

View Tips and Talking Points for Supporting a Patient’s Decision
to Enroll in a Clinical Trial Here

Featured Clinical Trials

Submission: State Society or Hem Onc Group webpage – Tagraxofusp AML 0423 clinical trial MED-05227 12/2024

Posted December 27, 2024

A Phase 2 Study of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Untreated CD123+ Acute Myeloid Leukemia (AML) Who Cannot Undergo Intensive Chemotherapy This multicenter open-label phase 2 study will evaluate Tagraxofusp (TAG) in combination with Venetoclax and Azacitidine (Ven/Aza) in adults with previously untreated CD123+ AML who are ineligible for intensive... Read More »

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Posted November 22, 2024

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine... Read More »

Treatment-Naïve CLL: Phase 3 Study of Sonrotoclax Plus Zanubrutinib Compared With Venetoclax Plus Obinutuzumab in Participants With TN Chronic Lymphocytic Leukemia (CELESTIAL)

Posted August 6, 2024

The CELESTIAL study is a multi-center randomized phase III trial to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia. In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive... Read More »

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

Posted May 20, 2024

This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator’s Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The... Read More »

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia

Posted February 8, 2024

This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead... Read More »